VALERIO TX overview

Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023: - 287,160 shares - € 156,554.06 - Number of executions on buy side on semester: 509 - Number of executions on sell side on semester: 492 - Traded volume on buy side on semester: 634,648 shares for € 258,705.74 - Traded volume on sell side on semester: 923,185 shares for € 402,719.91 As a...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), (“ Onxeo ” or “the Company ”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights. The Annual General Meeting followed the voting recommendations...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the availability of preparatory documents for its Combined General Meeting to be held on Tuesday, June 6, 2023 at 2:00 pm at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris. The notice of meeting, including the agenda and the...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “ Onxeo ” or the “ Company ”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the publication of the Company’s 2022 annual financial report. The 2022 annual financial report is available to the public on the Company’s website . About Onxeo Onxeo (Euronext Growth Paris: ALONX) is a...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX ), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today reported its consolidated results for the fiscal year ending December 31, 2022. Dr. Shefali Agarwal, Chairwoman of the Board of Directors and CEO , stated: “ 2022 was a pivotal year for our Company, with renewed governance. Thanks to the support of our two main and historical...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX ), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022 full-year results. The publication of the 2022 full-year results is postponed to Monday April 24, 2023, after market close. About Onxeo Onxeo (Euronext Growth Paris: ALONX) is a clinical-stage biotechnology company developing...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX ) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022 full-year results. The publication of the 2022 full-year results is postponed to April 21, 2023, after market close. About Onxeo Onxeo (Euronext Growth Paris: ALONX) is a clinical-stage biotechnology company...